



West Pharmaceutical Services (WST)

Updated May 27th, 2019 by Jonathan Weber

Key Metrics

Current Price:	\$116	5 Year CAGR Estimate:	-7.6%	Volatility Percentile:	64.4%
Fair Value Price:	\$51	5 Year Growth Estimate:	7.0%	Momentum Percentile:	84.1%
% Fair Value:	227%	5 Year Valuation Multiple Estimate:	-15.1%	Growth Percentile:	66.7%
Dividend Yield:	0.5%	5 Year Price Target	\$72	Valuation Percentile:	0.7%
Dividend Risk Score:	A	Retirement Suitability Score:	C	Total Return Percentile:	0.3%

Overview & Current Events

West Pharmaceutical Services manufactures packaging and components involved in the distribution and application of pharmaceuticals. The company's products include *Zenith Crystal*, a medical glass alternative, and *SmartDose*, an automatic medication delivery system. West Pharmaceutical was founded in 1923, is headquartered in Exton, Pennsylvania, and trades with a market capitalization of \$8.6 billion. The company has increased its dividend for 25 consecutive years, which qualifies it to be a Dividend Champion.

West Pharmaceutical Services reported its first quarter earnings results on April 25. The company reported that its revenues totaled \$444 million during the first quarter, which represents a revenue growth rate of 6.7% compared to the prior year's quarter. West Pharmaceutical Services' revenues were higher than what the analyst community had expected. Revenues were negatively impacted by adverse currency rate movements. Adjusted for that, West Pharmaceutical Services' organic revenues were up by a very strong 11% versus the prior year's quarter.

West Pharmaceutical Services generated adjusted earnings-per-share of \$0.74 during the first quarter, which represents an increase of 19% compared to the prior year's first quarter earnings-per-share of \$0.62.

West Pharmaceutical Services reiterated its revenue guidance of ~\$1.8 billion for 2019, while the earnings-per-share forecast has been lifted slightly, to a new range of \$2.80 - \$2.90.

Growth on a Per-Share Basis

Year	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2024
EPS	\$1.06	\$1.05	\$1.17	\$1.38	\$1.57	\$1.75	\$1.30	\$1.91	\$2.78	\$2.81	\$2.85	\$4.00
DPS	\$0.31	\$0.33	\$0.35	\$0.37	\$0.39	\$0.41	\$0.46	\$0.50	\$0.54	\$0.57	\$0.60	\$0.80
Shares	66	67	67	67	70	71	72	73	74	74	74	75

West Pharmaceutical grew its earnings-per-share at an attractive pace of 11.4% annually between 2009 and 2018. This included the recovery from the last financial crisis, though, when West Pharmaceutical Services' earnings-per-share growth rate was at an above-average level, during 2010 – 2014. During the last financial crisis, West Pharmaceutical Services' earnings-per-share declined by roughly 15%, which was a solid performance versus most other companies. West Pharmaceutical's earnings-per-share growth has been a bit uneven. Earnings-per-share rose by 46% during 2017, for example.

West Pharmaceutical projects a long-term organic sales growth rate in a range of 6% to 8%. We believe that this could be too optimistic, as West Pharmaceutical's revenues have grown at a slower pace of slightly less than 5% over the last 9 years. West Pharmaceutical Services' organic revenue growth rate during 2018 was also slightly lower than management's revenue growth target range. The company should nevertheless be able to maintain positive top line growth at a meaningful pace over the coming years. Revenue growth will be one source for higher earnings going forward, but a more favorable product mix will positively impact West Pharmaceutical's earnings growth as well. The company seeks to increase its revenues in the Proprietary Products segment, which has significantly higher margins than the Contract-Manufactured Products equivalent. In the long run, we believe, it is likely that West Pharmaceutical will deliver earnings-per-share growth that is higher than its revenue growth rate.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



West Pharmaceutical Services (WST)

Updated May 27th, 2019 by Jonathan Weber

Valuation Analysis

Year	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	Now	2024
Avg. P/E	17.1	18.1	17.8	17.2	23.7	26.1	43.8	38.1	36.0	34.9	40.7	18.0
Avg. Yld.	1.7%	1.7%	1.7%	1.6%	1.0%	0.9%	0.8%	0.7%	0.6%	0.6%	0.5%	1.1%

West Pharmaceutical Services has never been valued at an especially low valuation throughout the last decade, but in the 2009-2012 time frame, its valuation was at least reasonable, although shares still traded at a premium valuation relative to the broad market. More recently, West Pharmaceutical Services' valuation has risen to a very high level, which is neither justified by the company's earnings growth record during the last couple of years, nor by the company's growth outlook over the coming years. We forecast huge downside potential for the company's share price.

Safety, Quality, Competitive Advantage, & Recession Resiliency

Year	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2024
Payout	29.2%	31.4%	29.9%	26.8%	24.8%	23.4%	35.4%	26.2%	19.4%	20.3%	21.1%	20.0%


West Pharmaceutical Services' dividend payout ratio has never been high; the company has paid out less than one third of its net profits in the form of dividends during each year of the last decade. Coupled with the fact that the company continued to raise its dividend even during the last financial crisis, the dividend appears to be very safe. However, the yield is so low that the stock is still likely uninteresting for income investors.

West Pharmaceutical is not active in a cyclical industry, as demand for medical items and pharmacologic products is not dependent upon economic conditions. This explains why West Pharmaceutical was not impacted by the last financial crisis to a large degree, showcased by the fact that earnings-per-share declined by less than 15% peak-to-trough.

Final Thoughts & Recommendation

West Pharmaceutical Services is active in an industry that is poised to generate solid growth rates over the coming years, and is also largely invulnerable to recessions. West Pharmaceutical Services has a solid dividend growth track record. We still do not think that the company is attractive for income investors due to the very low dividend yield. Due to an almost absurdly high valuation, West Pharmaceutical Services earns a strong sell recommendation from us at the current price, although we would like the company around fair value.

Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



West Pharmaceutical Services (WST)

Updated May 27th, 2019 by Jonathan Weber

Income Statement Metrics

Year	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Revenue	1055.7	1104.7	1192.3	1266.4	1368.4	1421.4	1399.8	1509.1	1599.1	1717.4
Gross Profit	303.6	318.1	339.3	387.7	434.7	447.8	455.8	501.1	512.6	545.4
Gross Margin	28.8%	28.8%	28.5%	30.6%	31.8%	31.5%	32.6%	33.2%	32.1%	31.8%
SG&A Exp.	177.7	187.7	191.1	218.1	0	0	61.3	2.1	0	262.9
D&A Exp.	68.1	73.2	75.7	76.9	85.2	90	89.9	90.7	96.7	104.4
Operating Profit	106	106.5	119.1	142.9	398.8	411.7	362.7	468	480.2	240.3
Op. Margin	10.0%	9.6%	10.0%	11.3%	29.1%	29.0%	25.9%	31.0%	30.0%	14.0%
Net Profit	72.6	65.3	75.5	80.7	112.3	127.1	95.6	143.6	150.7	206.9
Net Margin	6.9%	5.9%	6.3%	6.4%	8.2%	8.9%	6.8%	9.5%	9.4%	12.0%
Free Cash Flow	29.9	64.5	33.9	55.4	64.7	70.8	80.8	49.2	132.5	288.6
Income Tax	13.5	13.6	23.5	32.7	40.2	47.2	26.3	54.4	80.9	41.4

Balance Sheet Metrics

Year	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Total Assets	1271	1294.3	1399.1	1564	1671.6	1669.7	1695.1	1716.7	1862.8	337.4
Cash & Equivalents	83.1	110.2	91.8	161.9	230	255.3	274.6	203	235.9	337.4
Accounts Receivable	138.7	126.4	147.2	175	185.7	179	181.4	200.5	253.2	N/A
Inventories	129.2	147	151.8	162.2	176.9	181.5	181.1	199.3	215.2	N/A
Goodwill & Int. Ass.	169.8	167.6	163.5	163.1	162.5	150.6	142.2	126.3	129.4	N/A
Total Liabilities	691.9	668.6	744.2	835.1	765.2	712.8	671.2	599.2	582.9	-1059
Accounts Payable	68.4	63.2	89.8	102.9	108	103.1	119.8	122	138.1	N/A
Long-Term Debt	379.6	358.4	349.4	411.5	373.5	335.5	298.2	228.6	197	0
Shareholder's Equity	579.1	625.7	654.9	728.9	906.4	956.9	1023.9	1117.5	1279.9	1396.3
D/E Ratio	0.66	0.57	0.53	0.56	0.41	0.35	0.29	0.20	0.15	0.00

Profitability & Per Share Metrics

Year	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Return on Assets	6.0%	5.1%	5.6%	5.4%	6.9%	7.6%	5.7%	8.4%	8.4%	18.8%
Return on Equity	13.6%	10.8%	11.8%	11.7%	13.7%	13.6%	9.7%	13.4%	12.6%	15.5%
ROIC	7.9%	6.7%	7.6%	7.5%	9.3%	9.9%	7.3%	10.8%	10.7%	14.4%
Shares Out.	66	67	67	67	70	71	72	73	74	74
Revenue/Share	14.54	15.05	16.11	17.64	19.17	19.52	18.97	20.12	21.10	22.78
FCF/Share	0.41	0.88	0.46	0.77	0.91	0.97	1.09	0.66	1.75	3.83

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.